Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

MedMira launches clinical trial for Multiplo TP/HIV self-test in Canada

MedMira (TSXV: MIR) has announced the launch of a clinical trial to evaluate its Multiplo TP/HIV rapid test for use as a self-test in Canada. Multiplo is a dual HIV and syphilis rapid self-test that delivers immediate...

July 7, 2025

Developments

Cyclacel highlights publication in Gut showing plogosertib is active in FLC

Cyclacel Pharmaceuticals (NASDAQ: CYCC; NASDAQ: CYCCP) has announced the publication of independent research in the peer-reviewed medical journal Gut demonstrating that plogosertib, a PLK1 inhibitor, is active in...

July 7, 2025

Developments

Cancer Cell highlights preclinical data of Tonix’s mTNX-1700 in gastric cancer models

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced the publication of a paper in the peer-reviewed journal Cancer Cell, presenting data demonstrating that treatment with murine TNX-1700 (mTNX-1700) increased survival...

July 2, 2025

Developments

BriaCell adds two key clinical sites to Phase 3 study of lead candidate in MBC

BriaCell Therapeutics (NASDAQ: BCTX, BCTXW, BCTXZ; TSX: BCT) has announced the addition of two major cancer centers to its ongoing pivotal Phase 3 clinical study of Bria-IMT plus immune checkpoint inhibitor versus...

July 2, 2025

Developments

Clearmind doses first patient in trial of MEAI-based treatment for AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that the first patient has been dosed in its Phase 1/2a clinical trial of its proprietary MEAI-based oral drug candidate, CMND-100, for the treatment of alcohol...

July 2, 2025

Developments

Medical City Dallas Hospital enhances surgical precision with Perimeter’s OCT imaging technology

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that Medical City Dallas Hospital—an award-winning, 899-bed acute care hospital in the Dallas-Fort Worth area—has adopted the company’s current...

July 2, 2025

Developments

Artelo reports positive first-in-human results for novel non-opioid pain therapy

Artelo Biosciences (NASDAQ: ARTL) has announced positive results from its first-in-human study evaluating its novel non-opioid candidate, ART26.12, for the treatment of persistent pain. ART26.12 is the first orally...

June 30, 2025

Developments

KalVista grants Pendopharm rights to commercialize sebetralstat for HAE

KalVista Pharmaceuticals (NASDAQ: KALV) has announced that it has entered into a licensing agreement with closely held Pendopharm to manage the regulatory approval process and commercialization of sebetralstat, an...

June 26, 2025

Developments

NMPA approves Theravance’s YUPELRI for COPD in China

Theravance Biopharma (NASDAQ: TBPH) has announced that China’s National Medical Products Administration (NMPA) has granted regulatory approval for YUPELRI, the company’s revefenacin inhalation solution for the treatment...

June 26, 2025

Developments

Clearmind adds leading Israeli clinical site to ongoing trial of CMND-100 in AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has added Tel Aviv Sourasky Medical Center (TASMC) to the list of clinical sites for its ongoing Phase 1/2a trial evaluating CMND-100—a proprietary MEAI...

June 24, 2025

Developments

Immunic reports positive long-term OLE data from trial of IMU-838 in RRMS

Immunic (NASDAQ: IMUX) has announced new, positive long-term open-label extension (OLE) data from its Phase 2 EMPhASIS trial of lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus...

June 24, 2025

Developments

ArriVent reports encouraging data from firmonertinib monotherapy study in NSCLC

ArriVent BioPharma (NASDAQ: AVBP) announced encouraging additional follow-up proof-of-concept data from its global Phase 1b FURTHER trial of first-line firmonertinib monotherapy in patients with non-small cell lung...

June 23, 2025

Developments

Compass Pathways meets primary endpoint in Phase 3 trial of psilocybin for TRD

Compass Pathways (NASDAQ: CMPS) announced that it has achieved the primary endpoint in the first of two ongoing Phase 3 trials evaluating COMP005 psilocybin for treatment-resistant depression (TRD). The ongoing Phase 3...

June 23, 2025

Developments

Firefly uncovers powerful new method of measuring SCD, MCI, and dementia in Alzheimer’s disease

Firefly Neuroscience (NASDAQ: AIFF) has announced a significant advancement in Alzheimer’s disease research: the company has identified a novel, objective method for measuring and distinguishing between subjective...

June 20, 2025

Developments

PharmaJet and Immuno Cure partner to advance needle-free HIV therapeutic DNA vaccine

Closely held PharmaJet announced that it has signed an agreement with closely held Immuno Cure, a developer of DNA vaccines. Under the agreement, Immuno Cure will use PharmaJet’s Tropis Intradermal (ID) Needle-Free...

June 19, 2025

Developments

Transgene advances TG4050 to Phase 2 in head and neck cancer trial

Transgene (Euronext Paris: TNG) announced the completion of initial patient screening in the Phase 2 portion of its ongoing Phase 1/2 clinical trial of TG4050—an individualized neoantigen therapeutic...

June 19, 2025

Developments

Telomir’s lead candidate prevents cellular aging in patient-derived cells from children with Progeria

Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data showing that Telomir-1 prevented cellular aging in patient-derived cells from children with progeria—Hutchinson-Gilford Progeria Syndrome (HGPS)—an...

June 18, 2025

Developments

MAIA enters into agreement with Roche to investigate THIO with Tecentriq

MAIA Biotechnology (NYSE American: MAIA) announced it has entered into a master supply agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to investigate the combination of MAIA’s telomere-targeting agent ateganosine...

June 18, 2025

Developments

Ekso Bionics’ Acceptance into NVIDIA Connect Program Bears Early Fruit

Ekso Bionics Holdings (NASDAQ:EKSO) has announced that it has successfully demonstrated initial proof-of-concept in integrating new AI-enabled capabilities across its portfolio of Enterprise Health and Personal Health...

June 18, 2025

Developments

USPTO issues patent for Lipella’s diagnostic technology

Lipella Pharmaceuticals (NASDAQ: LIPO) announced that on June 10, 2025 the U.S. Patent and Trademark Office (USPTO) issued Patent No. 12,326,492, titled Systems and Methods of Detecting Interstitial Cystitis, providing...

June 17, 2025

Developments

Cellectar reports updates on Phase 1 study of iopoffosine I 131 in pHGG

Cellectar Biosciences (NASDAQ: CLRB) announced initial results as of June 10, 2025, from its CLOVER-2 Phase 1 trial evaluating iopoffosine I 131 in relapsed/refractory pediatric high-grade glioma (pHGG) patients...

June 11, 2025

Developments

Adial’s lead AUD candidate advances toward Phase 3 trial

Adial Pharmaceuticals (NASDAQ: ADIL) announced that its lead investigational candidate—AD04—a therapeutic agent for alcohol use disorder (AUD) is progressing toward a Phase 3 trial. According to Adial, as part of its...

June 11, 2025

Subscribe